Patent US5314905A successfully refreshed from Google Patents.
US5314905A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pyropheophorbides conjugates and their use in photodynamic therapy
Assignee: Health Research Inc
•
Filing: 1992-11-09
•
Granted: 1994-05-24
•
Expires: 2012-11-09
Abstract
Abstract Conjugate are formed by covalently linking a target-specific compound to pyropheophorbide compound which conjugated are injected into a host and accumulate in tumor tissue to a higher degree than surrounding normal tissues. When the pyropheophorbide compound component of the conjugate is exposed to a particular wavelength of light the compound becomes cytotoxic destroying the tumor or diseased tissue without causing irreversible normal tissue damage. The pyropheophorbide compounds have been shown to have a variety of characteristics when used in photodynamic therapy. These characteristics are further improved when the compounds are bound to a target specific component such as a ligand capable of binding to a specific cellular receptor (e.g. growth hormones and growth factors) or an antibody capable of binding to a particular antigen.
Inventors
- 👤 Ravindra K. Pandey
- 👤 Thomas J. Dougherty
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 21:27
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/22; A; A61; A61K; A61K41/00; A61K41/0057; A61K41/0071; A61K51/00; A61K51/02; A61K51/04; A61K51/0474; A61K51/0485; A61P; A61P31/00; A61P31/12; A61P35/00; C07D519/00; A61K2123/00
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
58 words
A conjugate comprising a target-specific component covalently bound to a compound of formula I: ##STR7## wherein R 1 is CH 2 OR 2 where R 2 is a primary or secondary alkyl containing 1 to 20 carbons; and R 3 is --CO 2 R 4 where R 4 is H or an alkyl containing 1 to 20 carbons.
Claim 2
Dependent Claim
58 words
A conjugate comprising a target-specific component covalently bound to a compound of formula I: ##STR7## wherein R 1 is CH 2 OR 2 where R 2 is a primary or secondary alkyl containing 1 to 20 carbons; and R 3 is --CO 2 R 4 where R 4 is H or an alkyl containing 1 to 20 carbons.
Claim 3
Dependent Claim
36 words
The conjugate of claim 1, wherein the target-specific component is selected from the group consisting of a ligand capable of binding to a specific cellular receptor, and an antibody capable of binding to a particular antigen.
Claim 4
Dependent Claim
12 words
The conjugate of claim 2, wherein the antibody is a monoclonal antibody.
Claim 5
Dependent Claim
20 words
The conjugate of claim 2, wherein the ligand is selected from the group consisting of steroid hormones, and growth factors.
Claim 6
Dependent Claim
15 words
The conjugate of claim 2, wherein the conjugate is further attached to a detectable label.
Claim 7
Dependent Claim
29 words
The conjugate as claimed in claim 1, wherein R 1 is CH 2 --O--hexyl, R 2 is --CH 3 , and R 3 is --CO 2 CH 3 .
Claim 8
Dependent Claim
35 words
A method to effect the destruction of a target virus, cell or tissue, comprising: contacting said target with an effective amount of the conjugate of claim 1; and irradiating with light absorbed by said conjugate.
Claim 9
Dependent Claim
30 words
A pharmaceutical composition useful in treatment of a target virus, cells or tissue, comprising: an effective amount of the conjugate of claim 1 in admixture with a pharmaceutically acceptable excipient.
Claim 10
Dependent Claim
56 words
A conjugate comprising a target-specific component covalently bound to a compound of formula II: ##STR8## wherein R 5 is --OR 6 where R 6 is a primary or secondary alkyl containing 1 to 20 carbons and R 7 is --CO 2 R 8 where R 8 is H or an alkyl containing 1 to 20 carbons.
Claim 11
Dependent Claim
56 words
A conjugate comprising a target-specific component covalently bound to a compound of formula II: ##STR8## wherein R 5 is --OR 6 where R 6 is a primary or secondary alkyl containing 1 to 20 carbons and R 7 is --CO 2 R 8 where R 8 is H or an alkyl containing 1 to 20 carbons.
Claim 12
Dependent Claim
36 words
The conjugate of claim 9, wherein the target-specific component is selected from the group consisting of a ligand capable of binding to a specific cellular receptor, and an antibody capable of binding to a particular antigen.
Claim 13
Dependent Claim
12 words
The conjugate of claim 10, wherein the antibody is a monoclonal antibody.
Claim 14
Dependent Claim
20 words
The conjugate of claim 10, wherein the ligand is selected from the group consisting of steroid hormones, and growth factors.
Claim 15
Dependent Claim
15 words
The conjugate of claim 10, wherein the conjugate is further attached to a detectable label.
Claim 16
Dependent Claim
21 words
The compound as claimed in claim 9, wherein R 5 is --O--hexyl and R 7 is --CO 2 CH 3 .
Claim 17
Dependent Claim
35 words
The compound as claimed in claim 9, wherein R 5 is --O--(CH 2 ) 5 CH 3 and R 7 is selected from the group consisting of CO 2 CH 3 and --CO 2 H.
Claim 18
Dependent Claim
34 words
A method to effect the destruction of target virus, cells or tissue, comprising: contacting said target with an effective amount of the conjugate of claim 9; and irradiating with light absorbed by said conjugate.
Claim 19
Dependent Claim
30 words
A pharmaceutical composition useful in treatment of a target virus, cells or tissue, comprising: an effective amount of the compound of claim 9 in admixture with a pharmaceutically acceptable excipient.
Claim 20
Independent Claim
139 words
A method of treating a human with abnormal cells which replicate at an abnormally high rate, comprising the steps of: administering to the human therapeutically effective amount of a conjugate comprising a target-specific component covalently bound to a compound of formula II ##STR9## wherein R 5 is OR 6 where R 6 is a primary or secondary alkyl containing 5 to 20 carbons and R 7 is --CO 2 R 8 where R 8 is H or --CH 3 ; allowing the conjugate to accumulate on the abnormal cells; and irradiating the conjugate with a wavelength of light which is absorbed by the compound of formula II and thereby generating a cytotoxic effect with respect to the abnormal cells, wherein the conjugate is administered in an amount in the range of 0.01 mg/kg to 1.0 mg/kg of body weight.
Claim 21
Independent Claim
139 words
A method of treating a human with abnormal cells which replicate at an abnormally high rate, comprising the steps of: administering to the human therapeutically effective amount of a conjugate comprising a target-specific component covalently bound to a compound of formula II ##STR9## wherein R 5 is OR 6 where R 6 is a primary or secondary alkyl containing 5 to 20 carbons and R 7 is --CO 2 R 8 where R 8 is H or --CH 3 ; allowing the conjugate to accumulate on the abnormal cells; and irradiating the conjugate with a wavelength of light which is absorbed by the compound of formula II and thereby generating a cytotoxic effect with respect to the abnormal cells, wherein the conjugate is administered in an amount in the range of 0.01 mg/kg to 1.0 mg/kg of body weight.
Claim 22
Dependent Claim
54 words
The method as claimed in claim 18 wherein the conjugate is administered at timed intervals in the range of from every 3 hours to every 72 hours for over a period of from 1 day to 30 days and wherein the wavelength of the light is in the range of 600 to 700 nm.
Claim 23
Dependent Claim
30 words
The method as claimed in claim 18, wherein R 5 is --O--hexyl and R 7 is --CO 2 H and wherein the wavelength of the light is about 660 nm.
References Cited (Backward Citations)
US4649191A
Cited
US4883790A
Cited
US4920143A
Cited
US5002962A
Cited
US5093349A
Cited
US5198460A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-05-23 | 1997-11-22 | 1998-05-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-05-23 | 2001-11-22 | 2002-05-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-05-23 | 2005-11-22 | 2006-05-24 | $7700.00 | Window Closed / Lapsed |